Effect of levosimendan in experimental verapamil- induced myocardial depression

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

Volumn 18, Issue 1, 2010, Pages

  Kurola, Jouni ^a   Leppikangas, Heli ^b   Magga, Jarkko ^a   Lindgren, Leena ^b   Kiviniemi, Vesa ^c   Rutanen, Juha ^a   Ruokonen, Esko ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VERAPAMIL;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HEART ARREST; SWINE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; DISEASE MODELS, ANIMAL; HEART ARREST; HYDRAZONES; PYRIDAZINES; SWINE; VERAPAMIL;

EID: 77949449211     PISSN: None     EISSN: 17577241     Source Type: Journal    
DOI: 10.1186/1757-7241-18-12     Document Type: Article

References (30)

1. Watson WA, Litovitz T, Rodgers GC, Klein-Schwartz W, Reid N, Youniss J, Flanagan A, Wruk KM. 2004 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005, 23(5):589-666. 10.1016/j.ajem.2005.05.001, 16140178.
2. Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer JC, Drab A, Benson BE. Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001, 19:337-395. 10.1053/ajem.2001.25272, 11555795.
3. Litovitz TL, Klein-Schwartz W, Rodgers GC, Cobaugh DJ, Youniss J, Omslaer JC, May ME, Woolf AD, Benson BE. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002, 20(5):391-452. 10.1053/ajem.2002.34955, 12216043.
4. Lip GY, Ferner RE. Poisoning with anti-hypertensive drugs: calcium antagonists. J Hum Hypertens 1995, 9:155-161.
5. Gay R, Algeo S, Lee R, Olajos M, Morkin E, Goldman S. Treatment of verapamil toxicity in intact dogs. J Clin Invest 1986, 77:1805-1811. 10.1172/JCI112505, 370537, 3011861.
6. Varpula T, Rapola J, Sallisalmi M, Kurola J. Treatment of serious calcium channel blocker overdose with levosimendan, a calcium sensitizer. Anesth Analg 2009, 108:790-792. 10.1213/ane.0b013e3181931737, 19224785.
7. Schoffstall JM, Spivey WH, Gambone LM, Shaw RP, Sit SP. Effects of calcium channel blocker overdose-induced toxicity in the conscious dog. Ann Emerg Med 1991, 20:1104-1108. 10.1016/S0196-0644(05)81384-8, 1928882.
8. Kivistö KT, Neuvonen PJ, Tarssanen L. Pharmacokinetics of verapamil in overdose. Hum Exp Toxicol 1997, 16:35-37. 10.1177/0960327197016001071, 9023574.
9. Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Crit Care Med 1988, 16:246-251.
10. Neugebauer G. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res 1978, 12:247-254. 10.1093/cvr/12.4.247, 657182.
11. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995, 27:1859-1866. 10.1016/0022-2828(95)90009-8, 8523447.
12. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgmann C, Serimaa R, Annila A, Rosevear PR, Drakenberg T, Pollesello P, Kilpelainen I. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001, 276:9337-9343. 10.1074/jbc.M007484200, 11113122.
13. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Lindén IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995, 25:794-801. 10.1097/00005344-199505000-00016, 7630157.
14. Morelli A, De Castro S, Teboul J-L, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietrapaoli P. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005, 31:638-644. 10.1007/s00134-005-2619-z, 15812624.
15. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994, 81:974-987. 10.1097/00000542-199410000-00025, 7943849.
16. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000, 52:213-217. 10.1211/0022357001773715, 10714952.
17. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999, 79:609-34.
18. Hearse DJ, Tosaki A. Free radicals and calcium: Simultaneous interacting triggers as determinants of vulnerability to reperfusion-induced arrhythmias in the rat heart. J Mol Cell Cardiol 1988, 20:213-223. 10.1016/S0022-2828(88)80054-3, 3398055.
19. Soei LK, Sassen LM, Fan DS, van Veen T, Krams R, Verdouw PD. Myofibrillar Ca2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation 1994, 90:959-69.
20. Rosen MR, Wit AL, Hoffman BF. Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am Heart J 1975, 89:665-673. 10.1016/0002-8703(75)90514-1, 1091129.
21. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998, 98:2141-47.
22. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991, 325:1468-1475.
23. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, . the Vesnarinone Study Group Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993, 329:149-155. 10.1056/NEJM199307153290301, 8515787, the Vesnarinone Study Group.
24. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997, 333:249-259. 10.1016/S0014-2999(97)01108-4, 9314042.
25. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005, 111:1504-1509. 10.1161/01.CIR.0000159252.82444.22, 15781741.
26. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W, . on behalf of the Study Investigators Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000, 102:2222-2227. on behalf of the Study Investigators.
27. Gruhn N, Nielsen Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J CardiovascPharmacol 1998, 31:741-749.
28. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 2003, 17:111-113. 10.1023/A:1025379400395, 14562823.
29. Tanen D, Ruha A-M, Curry S, Graeme KA, Reagan CG. Hypertonic sodium bicarbonate is effective in the acute management of verapamil toxicity in a swine model. Ann Emerg Med 2000, 36(6):547-53. 10.1067/mem.2000.109509, 11097693.
30. Hughes HC. Swine in cardiovascular research. Lab Anim Sci 1986, 36:348-350.